Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis
Comments are closed.